HIV1 3XL DIAG


If you want to support NGYX Non-Profit initiative by advertising on this WEB site Click Here!


NGYX I.C. HIV1 3XL DIAG.


This Section is still currently under developpement. What we want to go for are the following:


Free submission of  HIV1 PR-RT nucleotide sequence. We will align it vs. HXB2 firstwith a proprietary software package. If there are problems (e.g. frameshift) we will let you know. Otherwise you will receive a MS-Excel file with the alignment and some additional info (Clade, Genotype = Mutational Pattern vs. HXB2 and WHO + FDA listed survey mutations).

Extended HIV1 Drug Resistance Diagnostic PR-RT Inhibitors (FDA approved; 3XL). This will top basic level described in point I + Trugene, VircoTYPE, ANRS, Viroseq, IAS, REGA, Stanford and NGYX I.C. predictions.


Meanwhile if you  want to challenge your skills in identifying  your own HIV1 Drug Resistance Prediction System we propose  datasets of Genotype/Phenotypes. Click HERE!

NGYX I.C. details / Coordinates.

Company N°: BE 0537.471.159

Postal Adress:  NGYX I.C. (P. LECOCQ ),rue des Hausseurs 10, B-4550 Nandrin, BELGIUM. Email:  Info@NGYX.EU              Tel. / GSM: +32 498 532496 IBAN: BE63 7506 5746 0708   BIC:AXABBE22

Email  us: Click Here!